If you have wet age-related macular degeneration (wet AMD) or another disease of the retina, your doctor may recommend treatment with an anti-VEGF drug. VEGF, or vascular endothelial growth factor, is ...

CHICAGO — The number of injections required for the successful treatment of neovascular age-related macular degeneration could be reduced considerably with experimental therapies, new research shows.

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

Add Yahoo as a preferred source to see more of our stories on Google. Current treatments sometimes fail to help people with "wet" age-related macular degeneration -- and researchers now think they ...

A single injection of a gene therapy was well tolerated and showed the potential to control exudation in patients with neovascular age-related macular degeneration (wet AMD). A single subretinal dose ...

Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The medication has ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This condition affects the central part of the retina, known as the macula, which is ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration-- and researchers now think they know why. Wet AMD is caused by an overgrowth of blood vessels in the ...